Can Gram-Negative Bacteria Develop Resistance to Antimicrobial Blue Light Treatment?

Int J Mol Sci. 2021 Oct 27;22(21):11579. doi: 10.3390/ijms222111579.

Abstract

Antimicrobial blue light (aBL) treatment is considered low risk for the development of bacterial resistance and tolerance due to its multitarget mode of action. The aim of the current study was to demonstrate whether tolerance development occurs in Gram-negative bacteria. We evaluated the potential of tolerance/resistance development in Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa and demonstrated that representative Gram-negative bacteria may develop tolerance to aBL. The observed adaption was a stable feature. Assays involving E. coli K-12 tolC-, tolA-, umuD-, and recA-deficient mutants revealed some possible mechanisms for aBL tolerance development.

Keywords: Escherichia coli; Klebsiella pneumoniae; Pseudomonas aeruginosa; antimicrobial blue light; resistance; tolerance.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Bacterial / genetics*
  • Escherichia coli Proteins / genetics
  • Gram-Negative Bacteria / genetics*
  • Light
  • Phototherapy / methods

Substances

  • Anti-Bacterial Agents
  • Escherichia coli Proteins